Celltrion Healthcare showcases data supporting the efficacy and safety of Truxima® (CT-P10, biosimilar rituximab) in advanced follicular lymphoma and rheumatoid arthritis
14.6.2017 08:02 | Business Wire
New data presented at the International Conference on Malignant Lymphoma (ICML) and the European League Against Rheumatism (EULAR) congress 2017 demonstrate that CT-P10 is comparable to reference rituximab in terms of efficacy and safety in both oncology and autoimmune disease indications. 1,2,3
The data from the randomised, double-blind, controlled phase III study in 140 advanced FL patients, presented at the ICML in Lugano, Switzerland, showed that CT-P10 was non inferior in terms of efficacy compared to reference rituximab, when each were given in combination with standard chemotherapy of cyclophosphamide, vincristine and prednisone (CVP) in patients with previously untreated advanced FL over eight cycles.1
The findings from the study also showed that the safety profile, pharmacokinetics , pharmacodynamics and immunogenicity of CT-P10 were comparable to those of reference rituximab.1
Prof. Coiffier, Head of the Department of Hematology at Hospices Civils de Lyon, France said: “The data presented add to the increasing wealth of evidence for biosimilar rituximab and demonstrate that CT-P10 was non-inferior in terms of efficacy and comparable in pharmacokinetics and safety to the reference rituximab for patients with advanced stage follicular lymphoma. Switching to biosimilar rituximab presents opportunities for healthcare systems across the world to reduce the costs associated with oncology treatments, paving the way for greater patient access for new innovative medicines.”
Findings showing comparable long-term efficacy and safety between CT-P10 and reference rituximab in RA patients treated over 48 weeks were also presented at EULAR. No clinically meaningful differences were found between the respective groups who took part in the randomised 372-patient study.2
Dr Kwon, Medical Director of Celltrion Healthcare, said: “Our studies consistently demonstrate the equivalence and comparability of our biosimilar rituximab, CT-P10, to reference rituximab. We are the only company that is able to proudly state that we have conducted phase III clinical trials looking into the safety and efficacy of its biosimilar in two indications – rheumatoid arthritis and non-Hodgkin’s lymphoma, which is a testament to our commitment to providing quality biosimilar treatments for patients supported by robust clinical data.”
Alongside the data demonstrating sustained efficacy over 48 weeks presented at the congress, a post-hoc analysis3 investigating the impact of body mass index (BMI) on clinical response using data from the phase III randomised controlled trial (RCT) that demonstrated clinical equivalence between a biosimilar rituximab, CT-P10 and reference rituximab4 indicates that clinical response to both biosimilar and reference is unaffected by BMI over 48 weeks. These data are in contrast to the known association between high BMI and inadequate clinical response to anti-tumour necrosis factor (TNF) agents, and suggest that rituximab is an effective treatment option for obese RA patients who do not respond well to anti-TNF agents.4
Dr Dae-Hyun Yoo, Global Principal Investigator of the RA study and Professor of Medicine at Hanyang University Hospital for Rheumatic Diseases, College of Medicine, Hanyang University, Republic of Korea, said: “The data in support of CT-P10 are very encouraging, as it means that biosimilar rituximab could prove a reasonable therapeutic alternative to patients with rheumatoid arthritis who have a high BMI and have had an inadequate response to anti-TNFs.”
Notes to editors:
About CT-P10 (biosimilar rituximab)
CT-P10 is a mAb that targets CD20, a protein found on the surface of most B cells. Overactive B cells can stimulate attack of healthy cells in immune-related diseases such as RA. B cells are also implicated in some types of hematological cancer including NHL and CLL. B cells express CD20 at many stages of their development making the protein a good target for treatments.
CT-P10 is approved in the EU for the treatment of people with NHL, CLL, RA, granulomatosis with polyangiitis and microscopic polyangiitis. Further details of the approved indications and safety information for CT-P10 are available in the summary of product characteristics (SmPC).5
About advanced follicular lymphoma
Follicular lymphomas are the second most common subtype of nodal lymphoid malignancies in Western Europe6 and are a subtype of non-Hodgkins lymphoma.7 Follicular lymphoma is a slow-growing lymphoma that develops from B lymphocytes (B cells). It is characterised by painless swelling of the lymph nodes, fever for no apparent reason, drenching night sweats, fatigue, infections and bleeding. Most cases are advanced at the time of diagnosis but since the arrival of rituximab, overall survival has increased to over 20 years. It is called ‘follicular’ lymphoma because the abnormal lymphocytes often collect in lymph nodes in clumps that are known as ‘follicles’. Follicular lymphoma is more common in people aged over 65, but it can occur in people of any age.
About rheumatoid arthritis
In Europe, more than 2.9 million people have rheumatoid arthritis (RA), many of whom are of working age. On average, every third person with RA becomes work disabled and up to 40 per cent leave work completely within 5 years of diagnosis.8 Although there is no cure for RA, there are many treatments that can reduce inflammation and ease pain. As with all rheumatic diseases early diagnosis and intervention is key.
About Celltrion Healthcare
Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines. For more information please visit: http://www.celltrionhealthcare.com/
1 Kim, Won Seog et al. Double blind, randomised, phase 3 study to compare efficacy and safety of the biosimilar CT-P10 rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma. The International Conference on Malignant Lymphoma. 2017. 223
2 Suh et al. Randomised double-blind study shows comparable long-term efficacy and safety between rituximab biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: 48 week results. Annual European Congress of Rheumatology (EULAR). 2017. SAT0146.
3 Yoo. et al. Rituximab is effective in the treatment of Rheumatoid Arthritis regardless of Body Mass Index. Annual European Congress of Rheumatology (EULAR). 2017. FRI0178
4 Yoo. et al. A randomized, controlled, double-blind, parallel-group, phase 3 Study to compare the pharmacokinetics, efficacy and safety between CT-P10, Rituxan and MabThera in patients with rheumatoid arthritis. Available at https://covalentdata.com/clinical-trial/NCT02149121.
5 Truxima concentrate for solution for infusion summary of product characteristics [last accessed June 2017]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004112/WC500222694.pdf.
6 Dreyling, M, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2011;22(suppl 6):vi59-vi63.
7 Kohrt HEK, Ugarte A. Follicular Lymphoma: a Guide for Patients. European Society for Medical Oncology. 2014. Available at: https://www.esmo.org/content/download/52236/963497/file/EN-Follicular-Lymphoma-Guide-for-Patients.pdf [Last accessed June 2017].
8 NRAS, European Fit for Work Report. Available at www.nras.org.uk/european-fit-for-work-report. [Last accessed June 2017].
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Ford Names New Chairman and CEO for Ford China; New Vice President of Powertrain Engineering23.8.2017 22:00 | Pressemelding
Ford Motor Company today announced a new chairman and CEO of Ford China and head of Powertrain Engineering as it continues to strengthen its global leadership team. Jason Luo is named chairman and CEO Ford China. In his new role, Luo will lead all of the company’s operations in Greater China including its import business, Lincoln, its passenger car joint venture Changan Ford, commercial vehicle investment in Jiangling Motors Corporation, and our operations in Taiwan. Luo, 51, joins Ford from Key Safety Systems, the fastest growing company in the automotive safety market, where he was global president and CEO for the past 10 years. While at Key Safety Systems, he led the business transformation and global expansion of the company and achieved significant revenue growth in China. Luo will be based in Shanghai, reporting to Peter Fleet, Ford group vice preside
Tech21 Announces New Collection Designed to Protect the Samsung Galaxy Note8 Drop After Drop.23.8.2017 17:30 | Pressemelding
Tech21, the leader in impact protection for mobile devices, today announced a new collection of innovative cases and screen shields for the Samsung Galaxy Note8 made of unique, patented impact protection materials that guarantee the most effective drop protection on the market. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170823005888/en/ Evo Tactical for Samsung Galaxy Note8 (Photo: Business Wire) Tech21 products are designed to protect, drop after drop. The company does this by using scientifically proven impact materials, innovative design and a rigorous testing methodology developed in partnership with the National Physical Laboratory. Tech21 cases are drop tested 20 times to ensure durability and long lasting protection able to withstand the multiple drops that occur in the everyday
2018 AQR Insight Award Call for Papers23.8.2017 15:45 | Pressemelding
AQR Capital Management, LLC (“AQR”) today began accepting submissions for the seventh annual AQR Insight Award. The AQR Insight Award recognizes and rewards exceptional academic papers that have practical applications and offer original, intelligent approaches to issues in the investment world. Up to three papers share a $100,000 annual prize. Winners are chosen by the AQR Insight Award Committee, a panel of senior members of the firm, many of whom are leading academic finance experts from top universities. AQR will accept papers on any investment-related topic as long as they deliver clear, significant insights. Papers must not be published before October 1, 2017. The deadline for entries is November 1, 2017. The Committee will then narrow the finalists to five papers, and the authors of those papers will be invited to present their research to
ANA Announces New Online Content "IS JAPAN COOL? DOU"23.8.2017 15:00 | Pressemelding
Today, All Nippon Airways Co., Ltd. (ANA), Japan’s largest and only 5-Star airline, is proud to announce the launch of its new online content “IS JAPAN COOL? DOU,” which illustrates traditional Japanese culture through the use of cutting-edge technology. This content can be seen on “IS JAPAN COOL?,” a website that promotes tourist destinations and popular Japanese cultures to the world. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170823005024/en/ "IS JAPAN COOL? DOU" TOP (Graphic: Business Wire) While Japan is widely known for its unique pop culture, “IS JAPAN COOL?,” which launched in 2012, has put much of its focus on promoting Japan’s modern culture. As the number of tourists visiting Japan exceeded 24 million people as of 2016, the project aims to provide a deeper understa
Emailage Receives $10 Million Growth Equity Investment to Accelerate Global Expansion23.8.2017 14:00 | Pressemelding
Emailage, the leading provider of global fraud prevention and identity verification using email address scoring, today announced that it has received a $10 million growth equity investment. Anthos Capital led the investment, with participation from Radian Capital, Wipro Ventures, Mucker Capital and Tallwave Capital. Emailage will use the funding to expand existing partnerships, further advance its powerful email address-based predictive scoring system, and accelerate growth in North America, EMEA, LATAM and other key markets. “This investment will allow us to continue our rapid growth, enhance our leadership position in the online fraud detection market and deliver significant fraud prevention capabilities to businesses around the world,” said Emailage CEO Rei Carvalho. Emailage’s Software-as-a-Service solution delivers powerful, real-time risk intelligence by leveraging the
Westinghouse to Provide Fuel to PSEG’s Salem Nuclear Generating Station Through Continued Partnership23.8.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has signed a nuclear fuel contract extension with PSEG, a major supplier of nuclear power in New Jersey, to continue providing fuel assemblies for both units at the Salem Nuclear Generating Station. “Westinghouse has been the single-source fuel provider for PSEG’s Salem plant since its start of operations more than 40 years ago, and we are pleased to continue to support this important and long-standing customer through the delivery of safe, reliable high-performance fuel,” said David Howell, president, Americas Region, and chief growth officer at Westinghouse. “This continued partnership is recognition of our reliable fuel performance and confirmation of the important trust PSEG has in Westinghouse.” Under the terms of the contract, Westinghouse will deliver its 17x17 Robust Fuel Assemblies, known as RFA-2. The design of
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom